NCT03338725

Effect and Associated Factors of the Clinical Pharmacy Model in the Incidence of Medical Errors

Effect and Associated Factors of the Clinical Pharmacy Model in the Incidence of Medical Errors in the Hospital Pablo Tobon Uribe- Colombia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 720 (actual)
• Sponsor: Universidad de Antioquia · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Medication errors are considered by WHO to be a subject that requires attention at all levels of care, in order to reduce the serious and preventable damage related to medication. These strategies are aimed at the patient's safety policy. In Colombia, at the regulatory level there is no standardized clinical pharmacy model where the role of the clinical pharmacist is described extensively and in detail, and in addition, data are unknown of the scope or direct effect of the incorporation of this model in the assistance in the results of health care. The Hospital Pablo Tobón Uribe, it is a highly complex institution in Medellin (Colombia), certified by Join Comission International (JCI), which requires the continuous interaction of the pharmacist in patient care, in order to avoid medication errors and contribute to patient safety indicators. In this sense, the hospital structured and implemented a clinical pharmacy model that establishes the activities of the pharmacist incorporated into the care team in the patient attention. Today this model is applied in the institution, however, it is necessary to know the effect of its application in the solution of drug-related problems (DRPs) or a negative outcome related to medicine. The objective of this study is to know the effect on patient safety of a clinical pharmacy model in a hospital of high complexity and framed in the WHO initiative to reduce these errors of medication.

Detailed description

A randomized controlled clinical trial of stepped wedge will be performed. Patients will be admitted according to the inclusion criteria. Randomization will be done at the cluster level (group) and the result measured in the participants within the cluster.

Conditions

• Pharmaceutical Services
• Medication Errors
• Drug-Related Side Effects and Adverse Reactions
• Outcome Assessment (Health Care)

Interventions

Type	Name	Description
OTHER	Clinical pharmacy model	Patients who are being monitored by a clinical pharmacy model

Timeline

• Start date: 2018-02-01
• Primary completion: 2019-05-30
• Completion: 2020-11-10
• First posted: 2017-11-09
• Last updated: 2020-11-12

Locations

1 site across 1 country: Colombia